News

The monoclonal antibody, Vedolizumab, antagonizes alpha4beta7 (-4ß7) integrin expressed on a subset of circulating white blood cells and treat most common types of inflammatory bowel diseases (IBD) such

As per the agreement, Roche will provide R&D funding and scientific support to BioLamina. The financial terms and conditions of the deal were undisclosed. Roche’s Biochemical Reagents and

Since 2008, DKSH Healthcare is providing Market Expansion Services to Advance Pharma in West Malaysia. The extended partnership between DKSH and Advance Pharma in Malaysia aims to demonstrate

The approved patent application, which is part of the ‘Pan’ patent family, is designed to restore vision in retinal degenerative conditions such as retinitis pigmentosa and dry age-related

Ajinomoto said based upon a successful proof-of-concept, the company has entered a full licensing agreement that allows for the in-house use of the system. Corynex uses the gram-positive

The licensing agreement provides miRagen with exclusive rights to an important discovery made in collaboration with the University of Glasgow and the University of Cambridge, enabling miRagen to

The agreement aims to manufacture eribulin mesylate as well as other developmental drugs. DSM Pharmaceutical Products president and CEO Alexander Wessels said, "We are delighted to be working

The partnership aims to provide drug developers with improved access to pharmaceutical nanomilling equipment and full pharmaceutical development capabilities. Particle Sciences pharmaceutical development president Robert Lee said the

FDA in the letter mentioned that it requires Mallinckrodt’s complete pharmacokinetic study comparing PENNSAID 2% to original PENNSAID 1.5%. FDA denied to review the similar pharmacokinetic studies submitted